US Bancorp
BTAI icon

US Bancorp’s BioXcel Therapeutics BTAI Stock Holding History

US Bancorp’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Hold
1
– – ﹤0.01% 4163
2025
Q4 		$2 Hold
1
– – ﹤0.01% 4032
2025
Q3 		$3 Hold
1
– – ﹤0.01% 3994
2025
Q2 		$2 Hold
1
– – ﹤0.01% 4152
2025
Q1 		$2 Sell
1
-1
-50% -$4 ﹤0.01% 4180
2024
Q4 		$12 Sell
2
-1,125
-100% -$9.4K ﹤0.01% 4143
2024
Q3 		$11K Sell
1,127
-27
-2% -$363 ﹤0.01% 3340
2024
Q2 		$23.6K Buy
1,154
+27
+2% +$904 ﹤0.01% 2992
2024
Q1 		$50.9K Hold
1,127
– – ﹤0.01% 2682
2023
Q4 		$53.2K Hold
1,127
– – ﹤0.01% 2648
2023
Q3 		$45.6K Buy
1,127
+247
+28% +$25K ﹤0.01% 2493
2023
Q2 		$93.7K Buy
880
+878
+43,900% +$292K ﹤0.01% 2229
2023
Q1 		$616 Hold
2
– – ﹤0.01% 3927
2022
Q4 		$709 Sell
2
-24
-92% -$5.8K ﹤0.01% 3962
2022
Q3 		$5K Sell
26
-12
-32% -$2.79K ﹤0.01% 3575
2022
Q2 		$8K Sell
38
-7
-16% -$1.47K ﹤0.01% 3413
2022
Q1 		$15K Sell
45
-7
-13% -$2.03K ﹤0.01% 3214
2021
Q4 		$17K Sell
52
-14
-21% -$6.01K ﹤0.01% 3191
2021
Q3 		$32K Sell
66
-21
-24% -$9.23K ﹤0.01% 2876
2021
Q2 		$41K Sell
87
-220
-72% -$120K ﹤0.01% 2767
2021
Q1 		$212K Sell
307
-16
-5% -$12.9K ﹤0.01% 1900
2020
Q4 		$238K Buy
323
+24
+8% +$18.7K ﹤0.01% 1800
2020
Q3 		$207K Buy
299
+153
+105% +$115K ﹤0.01% 1754
2020
Q2 		$124K Sell
146
-43
-23% -$28K ﹤0.01% 1992
2020
Q1 		$68K Buy
+189
New +$67.9K ﹤0.01% 2205

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

US Bancorp's BTAI Position: Q1 2026 in Review

US Bancorp held its BioXcel Therapeutics (BTAI) position steady in Q1 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #4163.

US Bancorp first reported a position in BTAI in Q1 2020 and has held it in 25 quarters since. The position peaked at $238K in Q4 2020. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • US Bancorp held 1 share of BioXcel Therapeutics worth $1 as of Q1 2026.
  • US Bancorp left its BioXcel Therapeutics share count unchanged in Q1 2026.
  • BioXcel Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #4163 holding.
  • US Bancorp first reported a position in BioXcel Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • US Bancorp's BioXcel Therapeutics position peaked at $238K in Q4 2020.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.